Following a strategic review of the business, Allergan has agreed to sell five of its dermatology brands to Almirall in a transaction worth up to US$650 M. The deal will allow the Irish pharmaceutical company to refocus its pipeline on its four core therapeutic areas –medical aesthetics, central nervous system, eye care and gastrointestinal. Almirall will gain a mix of mature and growth brands to build its core dermatology business, including a first-in-class acne antibiotic expected to be approved by the FDA in Q4 2018.